It has been estimated that in 2010, over two million patients with end-stage kidney disease may have faced premature death due to a lack of access to affordable renal replacement therapy, mostly dialysis. To address this shortfall in dialytic kidney replacement therapy, we propose a novel, cost-effective, and low-complexity hemodialysis method called allo-hemodialysis (alloHD). With alloHD, instead of conventional hemodialysis, the blood of a patient with kidney failure flows through the dialyzer’s dialysate compartment counter-currently to the blood of a healthy subject (referred to as a “buddy”) flowing through the blood compartment. Along the concentration and hydrostatic pressure gradients, uremic solutes and excess fluid are transferred from the patient to the buddy and subsequently excreted by the healthy kidneys of the buddy. We developed a mathematical model of alloHD to systematically explore dialysis adequacy in terms of weekly standard urea Kt/V. We showed that in the case of an anuric child (20 kg), four 4 h alloHD sessions are sufficient to attain a weekly standard Kt/V of >2.0. In the case of an anuric adult patient (70 kg), six 4 h alloHD sessions are necessary. As a next step, we designed and built an alloHD machine prototype that comprises off-the-shelf components. We then used this prototype to perform ex vivo experiments to investigate the transport of solutes, including urea, creatinine, and protein-bound uremic retention products, and to quantitate the accuracy and precision of the machine’s ultrafiltration control. These experiments showed that alloHD performed as expected, encouraging future in vivo studies in animals with and without kidney failure.
Conventional hemodialysis (HD) is one of the most resource-intensive therapies in medicine and remains inaccessible to a large share of the world’s population with kidney failure. Allo-hemodialysis (alloHD) is a novel hemodialysis concept in which the blood of a healthy volunteer (“buddy”) replaces manufactured dialysate, flowing counter-currently to the patient’s blood across a conventional dialyzer membrane. Uremic solutes and excess fluid move from the patient into the buddy’s circulation and are cleared by the buddy’s own kidneys, while bicarbonate and water-soluble vitamins diffuse back to the patient. By eliminating water treatment, dialysate production, and much of a conventional machine’s electromechanical complexity, alloHD has the potential to lower the cost, complexity, and environmental footprint of kidney replacement therapy. This review synthesizes the evidence for alloHD, spanning two-compartment urea and acid–base kinetic modeling, ex vivo bench testing of a low-cost prototype, and in vivo porcine studies of acute kidney injury, while describing a modeling extension to severe neonatal jaundice. We summarize buddy safety considerations as well as review ethical issues and caregiver/health-care professional acceptance data. Finally, we position alloHD within the broader movement toward more sustainable and personalized dialysis, and outline the translational steps required before first-in-human study.